Vivoryon Therapeutics N.V.

We are focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings.

At Vivoryon, we are developing small molecule inhibitors to prevent N3pE amyloid formation, rather than aiming to clear existing Abeta plaques6,7. In addition to blocking formation of this toxic Abeta species, these inhibitors also act through a second mechanism of action, targeting QPCTL, which inhibits neuroinflammation by modulating CCL2 activity. CCL2 is also a promoter of the tau pathology and increased levels of QPCTL and high pE-CCL2 levels correlate strongly with low cognitive (MMSE) scores in AD patients8.

Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer‘s disease and has been shown to improve working memory in a completed Phase 2a study, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis.